![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » J&J to Begin Phase 1 COVID-19 Vaccine Trial in Brazil
J&J to Begin Phase 1 COVID-19 Vaccine Trial in Brazil
![JohnsonJohnson_Logo.gif](https://www.fdanews.com/ext/resources/test/Device_Images5/JohnsonJohnson_Logo.gif?t=1626995791&width=430)
August 19, 2020
Johnson & Johnson subsidiary Janssen Pharmaceutical has received approval to launch a phase 1 COVID-19 vaccine trial in Brazil.
Janssen’s Ad26.COV2.S becomes the fourth vaccine hopeful to begin a trial in Brazil, which is second only to the U.S. in COVID-19 outbreak statistics. The country has recorded 3.4 million COVID-19 cases and more than 108,000 related deaths.
Janssen aims to recruit 6,000 participants for the Brazilian trial.
Upcoming Events
-
21Oct